cadherin related family member 2Genealiases: PCDH24 · PCLCK · PCLKC
Q-omics provides the consensus-scored CDHR2 profile across patient tissues and cancer cell-line models. CDHR2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CDHR2 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, CDHR2 RNA expression shows 17,987 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, HNSC, and TGCT as cancer lineages where CDHR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDHR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDHR2 survival associations across molecular data types. CDHR2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDHR2 RNA expression–survival associations across cancer types. High CDHR2 expression shows unfavorable associations in LUAD, MESO, BRCA, CESC and KICH, but favorable associations in KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for CDHR2 RNA expression.
This table summarizes CDHR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CDHR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDHR2 shows lower tumor expression in COAD, LIHC and KICH and higher tumor expression in HNSC, LUAD and BRCA. The HNSC box plot shows higher CDHR2 RNA expression in tumor versus normal tissue (log2 FC = +0.513, t-test p < 0.001).
This table shows molecular features associated with CDHR2 in patient tissues and cancer cell lines. In patient samples, CDHR2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CDHR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
